NHS to lose out on new drugs, pharma firm warns

The article reports that the UK's National Health Service (NHS) may miss out on new drugs due to a dispute over drug pricing deals between the government and pharmaceutical companies. According to Novartis, a major pharmaceutical firm, the NHS could be excluded from accessing new medications if the ongoing negotiations on drug pricing are not resolved. The issue stems from the government's attempts to reach agreements with pharmaceutical companies on the pricing of their products, which are seen as crucial for the NHS's budget. The article highlights the tension between the government's efforts to control healthcare costs and the pharmaceutical industry's desire to maintain profitable pricing. This standoff could potentially deprive NHS patients of access to new and innovative treatments in the future. The article underscores the complex and often contentious nature of drug pricing negotiations, which have significant implications for the healthcare system and the patients it serves.